Abstract: Methods for preventing, treating or diagnosing Type 1 Diabetes (T1D) are described. Amyloid-producing bacteria within microbiota are inactivated. Amyloid-producing bacteria are inactivated in microbiota, gastrointestinal tract, bodily fluids or tissues. Type-1 Diabetes associated microbial product production or release by microbiota is prevented. Also described is inactivation of bacteria-derived T1DAMP present in microbiota, bodily fluids or tissues of a mammal. Release of bacteria-derived T1DAMP from biofilm or bacteria to gastrointestinal tract is inhibited. Entry of bacteria-derived T1DAMP to microbiota, gastrointestinal tract, bodily fluids or tissues of a mammal is inhibited.

Abstract: The invention relates to methods for immunomodulation of immunosuppressive tumor cell microenvironment and prevention of tumor microbiome effects through multiple pathways with DNase enzyme therapy. Methods for immunomodulation of immunosuppressive tumor cell microenvironment comprising administering an effective amount of deoxyribonuclease (DNase) enzyme, either alone or in combination with other immunomodulating agent.

Abstract: Methods for preventing, treating or diagnosing Type 1 Diabetes (T1D) are described. Amyloid-producing bacteria within microbiota are inactivated. Amyloid-producing bacteria are inactivated in microbiota, gastrointestinal tract, bodily fluids or tissues. Type-1 Diabetes associated microbial product production or release by microbiota is prevented. Also described is inactivation of bacteria-derived T1DAMP present in microbiota, bodily fluids or tissues of a mammal. Release of bacteria-derived T1DAMP from biofilm or bacteria to gastrointestinal tract is inhibited. Entry of bacteria-derived T1DAMP to microbiota, gastrointestinal tract, bodily fluids or tissues of a mammal is inhibited.

Abstract: The invention relates to the liver-specific delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of cell free DNA (cfDNA) accumulated in hepatic porto-sinusoidal circulation and the use of such liver-specific delivery and/or expression for treatment of various diseases and conditions, including cancer and neurodegeneration.

Abstract: The invention relates to methods for treatment of cancers utilizing a combination of a deoxyribonuclease enzyme and adoptive cell immunotherapy comprising cells expressing a chimeric antigen receptor (CAR) or a T cell receptor (TCR). In particular embodiments, the deoxyribonuclease enzyme can be given parenterally or encoded by a vector or secreted by a cell comprising TCR or CAR.

Abstract: The invention relates to the use of deoxyribonuclease (DNase) enzyme for inhibiting progression and for prevention and treatment of neurodegeneration.

Abstract: The invention relates to chemistry and pharmacology, specifically to a synthetic biologically active substance -7,9-dibromo-2,4-dioxo-1,2,3,4-tetrahydrochromeno[2,3-d]-pyrimidinium-10 acetate or succinate formula 1:1 Where X??CH3COO? or HOOCCH2CH2COO?, as well as its tautomeric, hydrated forms, solvate, complex compounds, adducts and salt forms, possessing antimicrobial activity, and the ability to penetrate bacterial biofilms. The compound is intended for the treatment of bacterial infections of the oropharynx, skin, and mucous membranes, urinary system, implants, respiratory system, gastrointestinal tract. osteomyelitis, sepsis, nosocomial and wound infections.

Abstract: The invention relates to the nervous system-specific delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of microbial and viral cell free DNA (cfDNA) accumulated in cerebrospinal fluid (CSF), brain and other parts of nervous system, with the use of such nervous-system specific delivery and/or expression for treatment of various diseases associated with protein misfolding.

Abstract: The present invention provides compositions that modulate gut microbiota and/or the activity of deoxyribonucleases (e.g., in the gastrointestinal tract) and are useful in the treatment of diseases and disorders related to the activity of deoxyribonucleases including, for example, neurodegenerative, inflammatory, and metabolic diseases and cancer.

Abstract: The present invention provides fractionated polymer compositions that have antibacterial, antifungal and antiviral activity. These compositions are useful in the treatment infectious diseases caused by pathogens and for other uses.

Abstract: The invention relates to pharmaceutical compositions comprising mono- and/or oligonucleotides, dosage forms, and methods for treating and preventing diseases.

Abstract: The invention relates to microbiology and medicine and can be used to prevent and treat diseases and conditions associated with disruption of normal (autochthonous) microflora (microbiota) in humans or animals. In particular, a solution for recovery or creation of the subject's microflora comprising an active component containing microorganisms isolated from the microflora of the subject or the donor, wherein the active component can be enriched with bacteriophages of said microflora and/or additional microorganisms of the microflora cultivated on a nutrient medium, while the additional microorganisms of the microflora include microorganisms of the microflora that are yet nonculturable in the absence of the host organism, is proposed.

Abstract: Methods for preventing, treating or diagnosing Type 1 Diabetes (T1D) are described. Amyloid-producing bacteria within microbiota are inactivated. Amyloid-producing bacteria are inactivated in microbiota, gastrointestinal tract, bodily fluids or tissues. Type-1 Diabetes associated microbial product production or release by microbiota is prevented. Also described is inactivation of bacteria-derived T1DAMP present in microbiota, bodily fluids or tissues of a mammal. Release of bacteria-derived T1DAMP from biofilm or bacteria to gastrointestinal tract is inhibited. Entry of bacteria-derived T1DAMP to microbiota, gastrointestinal tract, bodily fluids or tissues of a mammal is inhibited.

Abstract: The invention relates to diagnosis, prevention, and treatment of diseases and conditions associated with the functions of prion-like or Tetz-proteins.

Abstract: Provided herein are methods for assessing ageing process, lifespan, life expectancy, biological age and the rate of aging by determining pangenome gene alterations. Specifically, the methods comprising determination of the alteration of the gene composition in mammals and/or non-living genetic elements (NLGE) associated with mammals and at least one of the following: microbiota and/or NLGE associated with microbiota. The methods can be used for increasing lifespan and/or for inhibiting aging in mammals.

Abstract: The invention relates to pharmaceutical compositions comprising mono- and/or oligonucleotides, dosage forms, and methods for treating and preventing diseases.

Abstract: The invention relates to microbiology, and more particularly to nutrient media used for cultivating bacteria for the subsequent study thereof. A nutrient medium comprising a pancreatic digest of casein, a peptic digest of meat, a heart pancreatic digest, yeast extract, starch and water is characterized in that it additionally contains violuric acid and beef infusion, wherein the ratio of ingredients is (wt %): 0.3-1.0 pancreatic digest of casein; 0.1-1.5 peptic digest of meat; 0.1-0.9 heart pancreatic digest; 0.1-2.0 yeast extract, 0.3-0.8 starch; 0.001-0.05 violuric acid; 2.0-15 beef infusion; the remainder water. The nutrient medium can additionally contain 0.3-2.5 wt % agar-agar and/or 1-20 wt % whole or hemolyzed sheep red blood cells and/or 1-20 wt % whole or hemolyzed human red blood cells and/or 1-15 wt % horse blood serum. This provides for the simultaneous growth of the maximum possible number of bacteria present in an inoculate.

Abstract: Provided herein are methods for preventing or treating diseases, said methods comprising (i) inhibiting entry of bacteriophages and/or component(s) thereof into microbiota, bodily fluid(s) or tissue(s) of the mammals and/or (ii) inactivating or modifying bacteriophages and/or component(s) thereof present in microbiota, bodily fluid(s) or tissues of the mammals and/or (iii) inactivating or modifying bacteriophages and/or component(s) thereof in one or more of food, drinking water, water for washing, water for air humidification, air, or habitat object of the mammals.

Abstract: The invention relates to the use of a deoxyribonuclease (DNase) enzyme for prevention or amelioration of toxicity associated with various cytostatic and/or cytotoxic chemotherapeutic compounds and radiation therapy.

Abstract: The invention relates to fungicides and can be used for treating diseases caused by fungi, and also for preventing fungal damage to various materials and agricultural products. Claimed is an agent against fungal infections which is in the form of salts of 2,4-dioxo-5-arylideneamino-6-methyl-1,3-pyrimidine, where R is 4-NO2, 2-OH-5-NO2, 2-OH-3,5-Cl2, 5-Br-4-OH-3-OCH3, 2-OH-5-Cl, 2,4-Cl2, 3,5-Br2-2-OH. The result is an agent against fungal infections which has a broad spectrum of activity and is highly soluble, rendering it more effective for use in the form of solutions.